In contrast to the poor in vitro antiproliferative activity, the NF-κB inhibitor JSH-23 showed striking anti-HCC effects in reducing both tumor mass by 61% (from 39.29 to 15.21) and disseminated tumor foci by 96% (from 44.90 to 2.00) when compared with the vehicle-treated control, which showed nearly no inhibition. The gene discussed is NFKB1; the disease is hepatocellular carcinoma.